Our research expertise spans cancer genomics, DNA damage, RNA biology, and drug development. We are also expanding our focus on drug delivery, particularly through nanotechnology-based methods for delivering small RNA mimics and inhibitors.
News
- Function: Constitutive mTORC1 Activation in Skeletal Muscle Increases Inflammation but is not Sufficient to Impair Glucose Tolerance (Lai Lab)
- Nature Communications: Multifaceted roles of PDS5B in RAD51-dependent homology-directed DNA repair and replication fork protection (Sung Lab, Libich, Olsen, Wasmuth, Rao, et al)
- Nature Structural & Molecular Biology: CST complex promotes second-strand synthesis in break-induced replication (Sung Lab, Malkova, et al)
- Nature Communications: Break-induced replication forms long mutable single-strand DNA during meiosis (Malkova)
- Greehey CCRI Researcher Awarded Grant to Advance RNA-Based Therapy for Aggressive Pediatric Brain Cancer (Penalva)
Events
Greehey CCRI Spring ’26 Seminar Series: Reuben Harris, PhD (UTHSA)
Presentation title: “Progress on the development of novel drugs for viral proteases”
Greehey CCRI Seminar Series: Lingtao Jin, PhD (UTHSA)
Presentation title: “Kinase Signaling in Cancer Drug Resistance”